PubMed=26937552; DOI=10.1089/mab.2015.0077
Kato Y., Ogasawara S., Oki H., Honma R., Takagi M., Fujii Y., Nakamura T., Saidoh N., Kanno H., Umetsu M., Kamata S., Kubo H., Yamada M., Sawa Y., Morita K.-i., Harada H., Suzuki H., Kaneko M.K.
Novel monoclonal antibody LpMab-17 developed by CasMab technology distinguishes human podoplanin from monkey podoplanin.
Monoclon. Antib. Immunodiagn. Immunother. 35:109-116(2016)

PubMed=27031228; DOI=10.1371/journal.pone.0152912; PMCID=PMC4816300
Kato Y., Ogasawara S., Oki H., Goichberg P., Honma R., Fujii Y., Kaneko M.K.
LpMab-12 established by CasMab technology specifically detects sialylated O-glycan on Thr52 of platelet aggregation-stimulating domain of human podoplanin.
PLoS ONE 11:E0152912-E0152912(2016)

PubMed=27328060; DOI=10.1089/mab.2016.0006
Ogasawara S., Kaneko M.K., Honma R., Oki H., Fujii Y., Takagi M., Suzuki H., Kato Y.
Establishment of mouse monoclonal antibody LpMab-13 against human podoplanin.
Monoclon. Antib. Immunodiagn. Immunother. 35:155-162(2016)

PubMed=27564251; DOI=10.1089/mab.2016.0031
Ogasawara S., Kaneko M.K., Kato Y.
LpMab-19 recognizes sialylated O-Glycan on Thr76 of human podoplanin.
Monoclon. Antib. Immunodiagn. Immunother. 35:245-253(2016)

PubMed=28101903; DOI=10.1002/cam4.954; PMCID=PMC5313638
Kaneko M.K., Nakamura T., Honma R., Ogasawara S., Fujii Y., Abe S., Takagi M., Harada H., Suzuki H., Nishioka Y., Kato Y.
Development and characterization of anti-glycopeptide monoclonal antibodies against human podoplanin, using glycan-deficient cell lines generated by CRISPR/Cas9 and TALEN.
Cancer Med. 6:382-396(2017)